Selected research
Industry Research
LGR5 Antibody Industry Research Report 2026
Market perspective
The global LGR5 Antibody market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the LGR5 Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the LGR5 Antibody market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the LGR5 Antibody market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of LGR5 Antibody include Thermo Fisher Scientific, Merck, United States Biological, Proteintech, OriGene, NSJ Bioreagents, Miltenyi Biotec, HUABIO and GeneTex, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global LGR5 Antibody market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to LGR5 Antibody.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
LGR5 Antibody Market by Company
Thermo Fisher Scientific
Merck
United States Biological
Proteintech
OriGene
NSJ Bioreagents
Miltenyi Biotec
HUABIO
GeneTex
Boster Biological Technology
Bioss
Bio-Rad
BioLegend
Abcam
LGR5 Antibody Segment by Type
Polyclonal
Monoclonal
LGR5 Antibody Segment by Application
Western Blot
Immunoprecipitation
Immunofluorescence
Immunohistochemistry
Others
LGR5 Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global LGR5 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of LGR5 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of LGR5 Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of LGR5 Antibody companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Polyclonal
- Monoclonal
Applications
- Western Blot
- Immunoprecipitation
- Immunofluorescence
- Immunohistochemistry
- Others
Companies covered
- Thermo Fisher Scientific
- Merck
- United States Biological
- Proteintech
- OriGene
- NSJ Bioreagents
- Miltenyi Biotec
- HUABIO
- GeneTex
- Boster Biological Technology
- Bioss
- Bio-Rad
- BioLegend
- Abcam
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 LGR5 Antibody by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Polyclonal
- 2.2.3 Monoclonal
- 2.3 LGR5 Antibody by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Western Blot
- 2.3.3 Immunoprecipitation
- 2.3.4 Immunofluorescence
- 2.3.5 Immunohistochemistry
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 LGR5 Antibody Breakdown Data by Type
- 3.1 Global LGR5 Antibody Historic Market Size by Type (2021-2026)
- 3.2 Global LGR5 Antibody Forecasted Market Size by Type (2027-2032)
4 LGR5 Antibody Breakdown Data by Application
- 4.1 Global LGR5 Antibody Historic Market Size by Application (2021-2026)
- 4.2 Global LGR5 Antibody Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global LGR5 Antibody Market Perspective (2021-2032)
- 5.2 Global LGR5 Antibody Growth Trends by Region
- 5.2.1 Global LGR5 Antibody Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 LGR5 Antibody Historic Market Size by Region (2021-2026)
- 5.2.3 LGR5 Antibody Forecasted Market Size by Region (2027-2032)
- 5.3 LGR5 Antibody Market Dynamics
- 5.3.1 LGR5 Antibody Industry Trends
- 5.3.2 LGR5 Antibody Market Drivers
- 5.3.3 LGR5 Antibody Market Challenges
- 5.3.4 LGR5 Antibody Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top LGR5 Antibody Players by Revenue
- 6.1.1 Global Top LGR5 Antibody Players by Revenue (2021-2026)
- 6.1.2 Global LGR5 Antibody Revenue Market Share by Players (2021-2026)
- 6.2 Global LGR5 Antibody Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of LGR5 Antibody Head Office and Area Served
- 6.4 Global LGR5 Antibody Players, Product Type & Application
- 6.5 Global LGR5 Antibody Manufacturers Established Date
- 6.6 Global LGR5 Antibody Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America LGR5 Antibody Market Size (2021-2032)
- 7.2 North America LGR5 Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America LGR5 Antibody Market Size by Country (2021-2026)
- 7.4 North America LGR5 Antibody Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe LGR5 Antibody Market Size (2021-2032)
- 8.2 Europe LGR5 Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe LGR5 Antibody Market Size by Country (2021-2026)
- 8.4 Europe LGR5 Antibody Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific LGR5 Antibody Market Size (2021-2032)
- 9.2 Asia-Pacific LGR5 Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific LGR5 Antibody Market Size by Country (2021-2026)
- 9.4 Asia-Pacific LGR5 Antibody Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America LGR5 Antibody Market Size (2021-2032)
- 10.2 South America LGR5 Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America LGR5 Antibody Market Size by Country (2021-2026)
- 10.4 South America LGR5 Antibody Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa LGR5 Antibody Market Size (2021-2032)
- 11.2 Middle East & Africa LGR5 Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa LGR5 Antibody Market Size by Country (2021-2026)
- 11.4 Middle East & Africa LGR5 Antibody Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Thermo Fisher Scientific
- 12.1.1 Thermo Fisher Scientific Company Information
- 12.1.2 Thermo Fisher Scientific Business Overview
- 12.1.3 Thermo Fisher Scientific Revenue in LGR5 Antibody Business (2021-2026)
- 12.1.4 Thermo Fisher Scientific LGR5 Antibody Product Portfolio
- 12.1.5 Thermo Fisher Scientific Recent Developments
- 12.2 Merck
- 12.2.1 Merck Company Information
- 12.2.2 Merck Business Overview
- 12.2.3 Merck Revenue in LGR5 Antibody Business (2021-2026)
- 12.2.4 Merck LGR5 Antibody Product Portfolio
- 12.2.5 Merck Recent Developments
- 12.3 United States Biological
- 12.3.1 United States Biological Company Information
- 12.3.2 United States Biological Business Overview
- 12.3.3 United States Biological Revenue in LGR5 Antibody Business (2021-2026)
- 12.3.4 United States Biological LGR5 Antibody Product Portfolio
- 12.3.5 United States Biological Recent Developments
- 12.4 Proteintech
- 12.4.1 Proteintech Company Information
- 12.4.2 Proteintech Business Overview
- 12.4.3 Proteintech Revenue in LGR5 Antibody Business (2021-2026)
- 12.4.4 Proteintech LGR5 Antibody Product Portfolio
- 12.4.5 Proteintech Recent Developments
- 12.5 OriGene
- 12.5.1 OriGene Company Information
- 12.5.2 OriGene Business Overview
- 12.5.3 OriGene Revenue in LGR5 Antibody Business (2021-2026)
- 12.5.4 OriGene LGR5 Antibody Product Portfolio
- 12.5.5 OriGene Recent Developments
- 12.6 NSJ Bioreagents
- 12.6.1 NSJ Bioreagents Company Information
- 12.6.2 NSJ Bioreagents Business Overview
- 12.6.3 NSJ Bioreagents Revenue in LGR5 Antibody Business (2021-2026)
- 12.6.4 NSJ Bioreagents LGR5 Antibody Product Portfolio
- 12.6.5 NSJ Bioreagents Recent Developments
- 12.7 Miltenyi Biotec
- 12.7.1 Miltenyi Biotec Company Information
- 12.7.2 Miltenyi Biotec Business Overview
- 12.7.3 Miltenyi Biotec Revenue in LGR5 Antibody Business (2021-2026)
- 12.7.4 Miltenyi Biotec LGR5 Antibody Product Portfolio
- 12.7.5 Miltenyi Biotec Recent Developments
- 12.8 HUABIO
- 12.8.1 HUABIO Company Information
- 12.8.2 HUABIO Business Overview
- 12.8.3 HUABIO Revenue in LGR5 Antibody Business (2021-2026)
- 12.8.4 HUABIO LGR5 Antibody Product Portfolio
- 12.8.5 HUABIO Recent Developments
- 12.9 GeneTex
- 12.9.1 GeneTex Company Information
- 12.9.2 GeneTex Business Overview
- 12.9.3 GeneTex Revenue in LGR5 Antibody Business (2021-2026)
- 12.9.4 GeneTex LGR5 Antibody Product Portfolio
- 12.9.5 GeneTex Recent Developments
- 12.10 Boster Biological Technology
- 12.10.1 Boster Biological Technology Company Information
- 12.10.2 Boster Biological Technology Business Overview
- 12.10.3 Boster Biological Technology Revenue in LGR5 Antibody Business (2021-2026)
- 12.10.4 Boster Biological Technology LGR5 Antibody Product Portfolio
- 12.10.5 Boster Biological Technology Recent Developments
- 12.11 Bioss
- 12.11.1 Bioss Company Information
- 12.11.2 Bioss Business Overview
- 12.11.3 Bioss Revenue in LGR5 Antibody Business (2021-2026)
- 12.11.4 Bioss LGR5 Antibody Product Portfolio
- 12.11.5 Bioss Recent Developments
- 12.12 Bio-Rad
- 12.12.1 Bio-Rad Company Information
- 12.12.2 Bio-Rad Business Overview
- 12.12.3 Bio-Rad Revenue in LGR5 Antibody Business (2021-2026)
- 12.12.4 Bio-Rad LGR5 Antibody Product Portfolio
- 12.12.5 Bio-Rad Recent Developments
- 12.13 BioLegend
- 12.13.1 BioLegend Company Information
- 12.13.2 BioLegend Business Overview
- 12.13.3 BioLegend Revenue in LGR5 Antibody Business (2021-2026)
- 12.13.4 BioLegend LGR5 Antibody Product Portfolio
- 12.13.5 BioLegend Recent Developments
- 12.14 Abcam
- 12.14.1 Abcam Company Information
- 12.14.2 Abcam Business Overview
- 12.14.3 Abcam Revenue in LGR5 Antibody Business (2021-2026)
- 12.14.4 Abcam LGR5 Antibody Product Portfolio
- 12.14.5 Abcam Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst